A VC fund with offices in the US and Asia manages roughly $70 million that it is actively seeking to invest. The initial investment size is highly variable though the firm is looking to provide up to $10+ million over the lifetime of the investment. The firm generally provides capital in the form of equity though they also have experience in working with convertible notes. The firm is interested in companies located either in the US or Asia. The firm’s primary focus is on private companies while public investments are also made selectively.

The fund is currently interested in companies developing Therapeutics, Diagnostics, Medical Devices, Healthcare IT, and R&D Services Companies. The firm is entirely opportunistic in terms of subsector and indication. In terms of phase of development, the firm is looking for companies with lead assets in the preclinical stage to companies that already have products on the market. The firm will consider companies in various stages on a case by case basis including seed financing.

The fund views the management team as one of the most important variables in selecting a potential investment. The firm looks for highly experienced and trustworthy management teams. The firm is highly interested in US based companies that are looking to expand into Asian markets or vice versa as member of the fund can add much value in these situations with their vast Asian network. However this US-Asia business development angle is not a criteria or requirement for the firm’s investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A pharmaceutical development company seeks to acquire assets in the therapeutics sector, and form new companies to develop these assets to commercialization. The firm primarily works with biotech companies based in North America.

The firm is interested in a broad range of therapeutic assets that have some level of proof of concept data (preferably in humans); the firm’s primary area of expertise is dermatology, and assets in the inflammation and oncology sectors are also highly of interest (but not immuno-oncology). In general the firm does not invest in infectious diseases, diseases of the nervous system, mental and behavioral disorders, or disease areas that require large trial sizes such as cardiovascular disease and diabetes.

When the firm acquires an asset, the firm typically keeps on the key team members associated with that asset and works with them throughout the development process.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital branch of a drug retailing chain looks to make strategic equity investments into companies of up to $5 million. The firm is generally stage agnostic although they prefer companies at or near commercialization. The firm is actively reviewing new investment opportunities and is open to consider companies from around the globe.

The firm is focused on investing in companies of mutual strategic benefit to Walgreens. This includes companies in sectors of Medical Devices, Point of Care Diagnostics, Healthcare Services, Pharmacy Innovation, and Sensors/Wearable devices. For medical devices and diagnostics the company prefers products that are near or have reached commercialization as the firm can add significant strategic value in distribution, marketing and sales. The firm is also very interested in products that will be sold directly to patients or devices/diagnostics that will be able to be used in the clinics. For wearable devices and sensors the firm is most interest in technologies with clinical value in terms of disease treatment and/or management. The firm is open to all indication types.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Mid-Western United States is looking to make equity investments into early stage companies ranging from $250,000 – $2.5 million. The firm is actively reviewing opportunities throughout the United States with a preference for companies located in the Mid-West.

The firm is looking for companies in sectors of Medical Devices, Diagnostics and Healthcare IT. In the device space, the firm is looking for companies with 510k regulatory pathways and is not interested in companies requiring PMA’s or therapeutic companies. The firm is open to all technologies types and indications within those areas. The firm looks to get involved in early stages of company formation. The firm’s current portfolio includes life science companies working with Genomic testing and in-vivo robotic surgical devices.

The firm is looking for privately held companies with experienced management teams. The firm looks to take a board seat following investment and is open to working with companies in filling and building out management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com